FUST MATTHEW K 1397266 Data last updated 2024-05-11 06:58:14 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-02 | 2023-05-31 | 2023-05-31 | 4 | Fust Matthew K | DIRECTOR | acq | 57000.0 | 52.29 | 5.82 | 0.0 | Direct | Common Stock | ATARA BIOTHERAPEUTICS, INC. | code A | 109000.0 | 97.97 (ATRA) |
| 2023-06-09 | 2023-06-07 | 2023-06-07 | 4 | Fust Matthew K | DIRECTOR | acq | 3860.0 | 12.72 | 0.55 | 0.0 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code A | 30355.0 | 70.81 (RARE) |
| 2023-06-09 | 2023-06-07 | 2023-06-07 | 4 | Fust Matthew K | DIRECTOR | dsp | 3300.0 | 10.87 | 0.47 | 51.82 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code D | 27055.0 | 70.81 (RARE) |
| 2023-06-21 | 2023-06-16 | 2023-06-16 | 4 | Fust Matthew K | DIRECTOR | acq | 6000.0 | 32.37 | 1.11 | 0.0 | Direct | Common Stock | CRINETICS PHARMACEUTICALS, INC. | code A | 18536.0 | 54.03 (CRNX) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Fust Matthew K | DIRECTOR | dsp | 12195.0 | 45.07 | 1.49 | 50.88 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code S | 14860.0
|
82.11 (RARE) |
| 2024-03-22 | 2024-03-20 | 2024-03-20 | 4 | Fust Matthew K | DIRECTOR | acq | 60000.0 | 100 | 8.98 | 20.92 | Direct | Common Stock | CRINETICS PHARMACEUTICALS, INC. | code M | 36036.0
|
66.8 (CRNX) |
| 2024-03-22 | 2024-03-20 | 2024-03-20 | 4 | Fust Matthew K | DIRECTOR | dsp | 60000.0 | 76.4 | 8.98 | 44.14 | Direct | Common Stock | CRINETICS PHARMACEUTICALS, INC. | code S | 18536.0
|
66.8 (CRNX) |
| 2024-04-02 | 2024-03-31 | 2024-03-31 | 4 | Fust Matthew K | DIRECTOR | acq | 150000.0 | 57.92 | 14.72 | 0.0 | Direct | Common Stock | ATARA BIOTHERAPEUTICS, INC. | code A | 259000.0 | 101.92 (ATRA) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-02 | 2023-05-31 | 2023-05-31 | 4 | Fust Matthew K | DIRECTOR | acq | 79500.0 | 100.0 | 8.11 | 1.53 | Direct | Non Qualified Stock Option (Right To Buy) | ATARA BIOTHERAPEUTICS, INC. | code A | 79500.0 | 97.97 (ATRA) |
| 2023-06-09 | 2023-06-07 | 2023-06-07 | 4 | Fust Matthew K | DIRECTOR | acq | 7110.0 | 100.0 | 1.0 | 51.82 | Direct | Stock Option (Right To Buy) | ULTRAGENYX PHARMACEUTICAL INC. | code A | 7110.0 | 70.81 (RARE) |
| 2023-06-21 | 2023-06-16 | 2023-06-16 | 4 | Fust Matthew K | DIRECTOR | acq | 17500.0 | 100.0 | 3.24 | 20.32 | Direct | Stock Option (Right To Buy) | CRINETICS PHARMACEUTICALS, INC. | code A | 17500.0 | 54.03 (CRNX) |
| 2023-09-14 | 2023-09-14 | 3 | Fust Matthew K | DIRECTOR | holding | 107374.0
|
0 | 3.19 | Direct | Stock Option (Right To Buy) | NEUMORA THERAPEUTICS, INC. | NA | 0.0 (NMRA) | |||
| 2023-09-18 | 2023-09-14 | 2023-09-14 | 4 | Fust Matthew K | DIRECTOR | acq | 27802.0 | 100.0 | 17.0 | Direct | Stock Option (Right To Buy) | NEUMORA THERAPEUTICS, INC. | code A | 27802.0 | 0.0 (NMRA) | |
| 2024-03-22 | 2024-03-20 | 2024-03-20 | 4 | Fust Matthew K | DIRECTOR | acq | 60000.0 | 0 | 8.98 | 20.92 | Direct | Stock Option (Right To Buy) | CRINETICS PHARMACEUTICALS, INC. | code M | 0.0
|
66.8 (CRNX) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)